CVS Health Corporation (CVS)
Health Care16 articles
Price chart
Why is CVS moving today?
+0.5%CVS is +0.5% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of just now
CVS Health Corporation (CVS) overview
CVS Health operates retail pharmacies, a pharmacy-benefits manager, and the Aetna insurance business.
CVS is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
CVS Health Corporation trades on the NYSE under the ticker symbol CVS. The most recent market data puts the share price at about $93.05. That is up 0.51% on the session. At that price the company is worth roughly $119.01B.
Over the past 52 weeks, CVS has traded between $69.51 and $110.68. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 24.5. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. CVS also pays a dividend. It yields around 2.87% at the current price.
Key statistics
Source: Yahoo Finance - quote as of just now
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch CVS
CVS is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each CVS story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. CVS is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves CVS
- Earnings. CVS reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from CVS.
- Sector news. Health Care stocks often move together, so a rival's news can move CVS too.
- Index weight. CVS is big enough to move the S&P 500 on its own.
Market Mood
This week for CVS
1 story about CVS Health Corporation in the last 7 days- CVS settles opioid case with DOJ for $315 millionLegalbearishinvesting.com
Follow CVS without checking every day
One email every Monday with the week's biggest moves and the stories behind them. Free, unsubscribe anytime.
Latest CVS news
CVS settles opioid case with DOJ for $315 million
CVS Health (CVS) has agreed to pay $315 million to settle a case with the U.S. Justice Department regarding the company's alleged improper distribution of opioid prescriptions. This settlement resolves claims that CVS pharmacies filled numerous invalid prescriptions, which had a significant impact on the opioid crisis in the United States. The U.S. government had accused the pharmacy chain of violating the Controlled Substances Act by improperly filling prescriptions that were not issued for a legitimate medical purpose or outside the usual course of professional practice. CVS stated that it is committed to supporting communities in combatting the opioid crisis and that this settlement does not include any admission of liability or wrongdoing by the company. By addressing this issue, CVS aims to focus on ensuring compliance and patient safety in the future. This settlement highlights the ongoing scrutiny placed on pharmacy chains and the healthcare sector regarding their role in the opioid epidemic, which is an important consideration for investors tracking regulatory impacts on the sector.
Read More: CVS settles opioid case with DOJ for $315 million
Cardinal Health (CAH) Rises on Extended CVS Distribution Deal
Cardinal Health (CAH) experienced an increase due to an extended distribution agreement with CVS Health. This new agreement extends their current partnership, likely improving Cardinal Health's revenue stability. The details of the agreement, including the duration and financial terms, were not disclosed. Such partnerships are critical for companies in the healthcare industry as they can impact product availability and pricing. These developments indicate a potential for revenue growth and enhanced market position for Cardinal Health.
Read More: Cardinal Health (CAH) Rises on Extended CVS Distribution Deal
Walgreens (WBA) Retreats as CVS Gains Suburban Pharmacy Market Share
Walgreens (WBA) is experiencing a downturn as CVS Health is reportedly expanding its presence in suburban pharmacies. The shift indicates a growing competitive landscape in the pharmacy sector. This change may influence consumer choices and operational strategies among pharmacy retailers. For investors, the increased competition could affect Walgreens' market share and revenue growth potential, highlighting the importance of monitoring competitive dynamics in the healthcare market.
Read More: Walgreens (WBA) Retreats as CVS Gains Suburban Pharmacy Market Share
CVS Health (CVS) Stock Rallies 3.7% on Analyst Upgrade
CVS Health (CVS) shares increased as much as 3.7% on Tuesday morning, currently up 3.4%. This surge is attributed to a positive rating from Jefferies analyst Brian Tanquilut, who set a $120 price target indicating 28% upside. The forecast includes an expected earnings per share (EPS) of at least $8.44 for 2027. CVS's recent increase in full-year guidance suggests strong growth potential, making its stock appealing for investors monitoring healthcare sector movements.
Read More: CVS Health (CVS) Stock Rallies 3.7% on Analyst Upgrade
CVS Health (CVS) Earnings Report Upcoming Analysts Focus on GLP-1
CVS Health (CVS) is scheduled to report earnings soon, with analysts paying close attention to GLP-1 drug momentum. This class of medications has been gaining traction as a weight-loss treatment, potentially impacting CVS's performance. Investors are keen to see how this will influence the company's overall outlook and revenue streams. Monitoring the earnings report may help provide insights into market trends in the healthcare sector.
Read More: CVS Health (CVS) Earnings Report Upcoming Analysts Focus on GLP-1
CVS (CVS) Reports 3% Net Income Margin, $100.4 Billion Revenue
CVS Health (CVS) reported a net income margin of approximately 3% for Q1 2026, generating $100.4 billion in revenue, with $32 billion from retail pharmacy sales. UnitedHealth (UNH) achieved a 6% net income margin for the same period, reporting $111.7 billion in revenue and a 2% increase from 2025. Both companies project positive growth, having raised their full-year guidance. The comparison highlights divergent business models and revenue trends, positioning both firms as potential investments in the healthcare sector.
Read More: CVS (CVS) Reports 3% Net Income Margin, $100.4 Billion Revenue
BlackRock Boosts CVS Group (CVS) Stake to 5% Ownership
BlackRock has increased its stake in CVS Group (CVS) to 5%. This move indicates BlackRock's confidence in CVS's long-term prospects. The increase may impact CVS's stock performance positively, as institutional interest can lead to enhanced market stability. Investors will be monitoring CVS for further developments in relation to this stake acquisition.
Read More: BlackRock Boosts CVS Group (CVS) Stake to 5% Ownership
BlackRock Stake in CVS (CVS) Falls Below 5% Amid Market Changes
BlackRock's ownership in CVS Group (CVS) has dropped below 5%. This reduction in stake may lead to changes in investor perception and stock dynamics. Institutional interest in CVS remains a key factor for market stability. Such a decline in ownership could potentially influence trading volumes and share price.
Read More: BlackRock Stake in CVS (CVS) Falls Below 5% Amid Market Changes
Crisis and Resilience Fund Offers £300,682 for Financial Support
West Devon Borough Council announced £300,682 in funding through its Crisis and Resilience Fund, which aims to provide emergency assistance and long-term support to those facing financial struggles. This fund replaces the Household Support Fund and includes crisis payments for low-income households, prioritizing Devon care leavers. An additional £20,000 is allocated to West Devon CVS for local support coordination, while £20,590 will go to Homemaker Southwest for welfare benefits and debt advice. The council emphasizes building financial resilience for residents as a key focus of this initiative.
Read More: Crisis and Resilience Fund Offers £300,682 for Financial Support
CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
CVS Health (CVS) announced the restoration of coverage for Eli Lilly's (LLY) Zepbound effective October 1 and will add the Foundayo obesity pill on June 1. This adjustment positions Lilly to compete equally with Novo Nordisk in the weight loss market, affecting an estimated 25 million to 30 million Americans. CVS aims for a 10% to 15% increase in savings across weight management treatments with the updated formulary. The decision follows a prior agreement with Novo Nordisk that made Wegovy the favored choice on CVS plans while previously excluding Zepbound.
Read More: CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
CVS Health (CVS) Stock Price Target Raised on Margin Recovery
Mizuho has increased the stock price target for CVS Health (CVS) due to anticipated margin recovery. This revision signifies confidence in the company's ability to improve profitability, which could have a positive effect on its share price. The adjustment reflects ongoing market assessments regarding CVS's performance and operational efficiency. Analysts' price targets are significant indicators of expected market movements and investor sentiment.
Read More: CVS Health (CVS) Stock Price Target Raised on Margin Recovery
Market Outlook: Earnings Week Ahead for Major Techs and AMD
Jim Cramer indicated that the previous earnings week showed positive results for major tech companies but cautioned that upcoming reports may be challenging. Companies like Advanced Micro Devices (AMD) and Eaton are expected to report strong quarters, with Cramer recommending buying AMD ahead of its earnings. Data center demand, particularly in the context of AI expansion, remains crucial for market performance. Additionally, the labor market is evolving, with artificial intelligence driving productivity and fewer hires, which could have significant implications for Federal Reserve policy.
Read More: Market Outlook: Earnings Week Ahead for Major Techs and AMD
US Health Insurers Surge on Medicare Payments Increasing 2.48%
US health insurers, including Humana (HUM), UnitedHealth Group (UNH), and CVS Health (CVS), saw their stocks rise following a Medicare Advantage payment increase. The Centers for Medicare & Medicaid Services (CMS) announced a net average increase of 2.48% in payments for 2027, up from a previously proposed 0.9%. This adjustment is projected to add approximately $13 billion in revenue to private insurers. The higher payments are aimed at providing financial relief amid rising medical costs, with Humana shares rising 6.4%, UnitedHealth by 8.8%, and CVS by 6.6%.
Read More: US Health Insurers Surge on Medicare Payments Increasing 2.48%
Eye Drops Recall Affects 3.1 Million Bottles Nationwide
Over 3.1 million bottles of eye drops have been recalled due to safety concerns, as confirmed by the FDA. The recall affects products sold at various retailers including Walgreens and CVS. This significant action raises concerns about public health and product safety in the pharmaceutical sector. The potential market impact may result in increased scrutiny and regulatory actions within the industry, affecting companies involved in eye drop manufacturing.
Read More: Eye Drops Recall Affects 3.1 Million Bottles Nationwide
CVS Health Stock Maintains Outperform Rating Amid FTC Settlement Progress
CVS Health's stock continues to hold an 'Outperform' rating as per Leerink analysts amid reported progress in the Federal Trade Commission (FTC) settlement. This development is significant as it may influence CVS's operational capabilities and market strategy. The stock performance may be impacted positively as the market reacts to the potential resolution of regulatory challenges. The specific timeframe and outcomes of the settlement have not been disclosed.
Read More: CVS Health Stock Maintains Outperform Rating Amid FTC Settlement Progress
CVS Group Responds to UK Veterinary Market Investigation Findings
CVS Group has issued a statement regarding the findings from the UK Competition and Markets Authority's (CMA) investigation into the veterinary market. The CMA's inquiry initiated in June 2023 highlighted concerns over competition and pricing in the sector. CVS Group is currently assessing the implications of the CMA's report on their operational practices. The outcome of this investigation may impact pricing strategies and competitive dynamics in the UK veterinary market.
Read More: CVS Group Responds to UK Veterinary Market Investigation FindingsMore Health Care stocks
Frequently asked questions
Is CVS Health Corporation in the S&P 500?
Yes. CVS Health Corporation trades as CVS and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is CVS in?
CVS sits in the Health Care sector of the S&P 500.
Where can I find the latest CVS news?
Right here. This page collects recent CVS news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is CVS Health Corporation's stock price?
CVS last traded at about $93.05. Prices move all through the session, so this is the latest quote rather than a live one.
What is CVS Health Corporation's market cap?
CVS is worth roughly $119.01B. Market cap is the share price times the number of shares outstanding.
What is CVS's P/E ratio?
CVS trades at a trailing P/E ratio of about 24.5. The ratio compares the share price with earnings per share over the past year.